These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 10385666

  • 1. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
    Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, Bain VG, Ehrinpreis MN, Albert D, Joh T, Witt K.
    Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
    [Abstract] [Full Text] [Related]

  • 2. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J.
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [Abstract] [Full Text] [Related]

  • 3. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC, Bacon BR, Goldin RD.
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [Abstract] [Full Text] [Related]

  • 4. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB, Hollinger FB.
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [Abstract] [Full Text] [Related]

  • 5. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.
    Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH.
    Hepatology; 1998 Oct; 28(4):1121-7. PubMed ID: 9755252
    [Abstract] [Full Text] [Related]

  • 6. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP.
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [Abstract] [Full Text] [Related]

  • 7. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB, Fu XX, Tian GS, Xu DZ, Hao LJ, Huangfu YS, Su CX.
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [Abstract] [Full Text] [Related]

  • 8. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S.
    Ann Intern Med; 1997 Nov 15; 127(10):875-81. PubMed ID: 9382365
    [Abstract] [Full Text] [Related]

  • 9. Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis C. Consensus Interferon Study Group.
    Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J, Albert D.
    Cytokines Cell Mol Ther; 1999 Dec 15; 5(4):211-6. PubMed ID: 10850385
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
    Farrell G, Cooksley WG, Dudley FJ, Watson K.
    J Viral Hepat; 1997 Sep 15; 4(5):317-23. PubMed ID: 9310930
    [Abstract] [Full Text] [Related]

  • 11. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, de la Mata M, Aljama P.
    Clin Nephrol; 2001 Mar 15; 55(3):220-6. PubMed ID: 11316242
    [Abstract] [Full Text] [Related]

  • 12. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group.
    Heathcote EJ, James S, Mullen KD, Hauser SC, Rosenblate H, Albert DG.
    Hepatology; 1999 Aug 15; 30(2):562-6. PubMed ID: 10421669
    [Abstract] [Full Text] [Related]

  • 13. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
    Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger FB, Mullen KD, Pimstone N, Albert D, Gardner S.
    Hepatology; 1998 Nov 15; 28(5):1411-5. PubMed ID: 9794929
    [Abstract] [Full Text] [Related]

  • 14. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy.
    Mathai J, Shimoda K, Banner BF, Mori M, Bonkovsky HL, Barnard GF.
    J Interferon Cytokine Res; 1999 Sep 15; 19(9):1011-8. PubMed ID: 10505743
    [Abstract] [Full Text] [Related]

  • 15. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J.
    N Engl J Med; 1998 Nov 19; 339(21):1493-9. PubMed ID: 9819447
    [Abstract] [Full Text] [Related]

  • 16. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group.
    Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, Everson GT, Hoefs JC, Fromm H, Black M, Foust RT, Pimstone NR, Heathcote EJ, Albert D.
    Am J Gastroenterol; 1999 Dec 19; 94(12):3583-8. PubMed ID: 10606323
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY.
    Am J Gastroenterol; 1999 Sep 19; 94(9):2496-500. PubMed ID: 10484014
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
    Reichard O, Glaumann H, Frydén A, Norkrans G, Wejstål R, Weiland O.
    J Hepatol; 1999 May 19; 30(5):783-7. PubMed ID: 10365802
    [Abstract] [Full Text] [Related]

  • 19. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS.
    Hepatology; 1996 Jul 19; 24(1):21-6. PubMed ID: 8707264
    [Abstract] [Full Text] [Related]

  • 20. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M, Chrobot A, Szaflarska-Szczepanik A.
    Med Sci Monit; 2000 Jul 19; 6(5):964-70. PubMed ID: 11208439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.